Herbs frequently used for non-small cell lung cancer.
收藏NIAID Data Ecosystem2026-03-07 收录
数据链接：
官方服务：
资源简介：
Herbs frequently used for non-small cell lung cancer.
应用场景：
创建时间：
2013-02-28
相关数据集
fon-2021-1417_supplementary data.docx
Table S1. PRISMA checklist Table S2. MEDLINE search strategy. Table S3. EMBASE search strategy Table S4. Proportion of patients by treatment modality (without timing) in resected, stages I-III NSCL
DataCite Commons2024-05-15 更新30
Dataset from A Phase I Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Docetaxel - a Phase I, Open-label, Dose-escalation Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy
To confirm the safety of BIBF 1120 at a dose level up to 200 mg x 2/day (i.e., overseas recommended Phase III dose for combination treatment) with standard therapy of docetaxel (60 mg/m2 and 75 mg/m2)
NIAID Data Ecosystem20
Additional file 1 of Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
Additional file 1. Treatment characteristics of the ICI group.
Figshare2021-12-04 更新10
Table_1_Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer.docx
Novel oncology drugs often fail to progress from preclinical experiments to FDA approval. Therefore, determining which preclinical or clinical factors associate with drug activity could accelerate dev
NIAID Data Ecosystem30
Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis
The current study aimed to evaluate the cost-effectiveness of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC)
Taylor & Francis Group2024-01-19 更新10
